001] and displayed higher AFP levels at find more the time of listing [median AFP level: 16 (range = 3-7154 μg/L) versus 13 μg/L (range = 1-552 μg/L), P = 0.04]. There was no other significant difference between the two groups at listing. Four HIV+ patients (19%) and 17 HIV− patients (26%) were

listed outside the Milan criteria (P = 0.50). Two of the 21 HIV+ patients (9%) and 10 of the 65 HIV− patients (15%) were listed outside the UCSF criteria (P = 0.42). TACE was performed in 13 of 21 HIV+ patients (61%) and in 38 of 65 HIV− patients (58%; P = 0.83). The mean number of courses did not differ significantly between HIV+ and HIV− patients [1 (range = 1-4) versus 1 (range = 1-3), P = 0.70]. After TACE, an RF procedure was performed in 8 of 21 HIV+ patients (38%) and in 15 of 65 HIV− patients (23%; P = 0.18). A trend toward a higher dropout

rate was observed among HIV+ listed patients versus HIV− listed patients [5/21 (23%) versus 7/65 (10%), P = 0.08]. The times to dropout from listing were similar in the two groups [median time: 6 months (range = 1-14 months) in HIV+ patients and 6.5 months (range = 3-11 months) in HIV− patients, P = 0.92]. Among HIV+ patients, AFP levels at listing were significantly higher in those Ferrostatin-1 datasheet who dropped out versus those who received a transplant [median AFP level: 98 (range = 3-7154 μg/L) versus 12 μg/L (range = 3-934 μg/L), P = 0.03]. This difference was not observed in HIV− patients [median

AFP level: 18 (range = 8-60 μg/L) versus 13 μg/L (range = 1-552 μg/L), check details P = 0.99]. No other differences were detected at listing. For patients on the waiting list, a monthly rise in AFP levels to >15 μg/L was reported to have poor prognostic value21 and was found in 4 of 5 HIV+ patients (80%) who dropped out and in 4 of 11 HIV+ patients (36%) who underwent transplantation (P = 0.03). Only one patient (without AFP progression) on the waiting list dropped out because of progression from controlled HIV infection to AIDS. Among HIV− patients, AFP progression > 15 μg/L per month was present in 4 of 6 patients (67%) who dropped out and in 12 of 52 patients (23%) who underwent transplantation (P = 0.02). In univariate analysis, except for AFP progression > 15 μg/L per month, no factor was predictive of patient dropout on the waiting list. By the last follow-up consultation (in January 2010), 16 HIV+ patients and 58 HIV− patients had undergone transplantation. Seventy-four of the 86 listed patients (86%) received a transplant (16 HIV+ patients and 58 HIV− patients). HIV+ transplant patients were younger than HIV− patients [median age: 50 (range = 43-63 years) versus 58 years (range = 37-72 years), P< 0.002], but preoperatively, there were no other differences between the HIV+ and HIV− patients, particularly with respect to AFP levels [median AFP level: 11.5 (range = 3-934 μg/L) versus 13 μg/L (range = 1-552 μg/L), P = 0.73].